Betapace, Betapace AF (sotalol) dosing, indications, interactions, adverse effects, and more (original) (raw)

All Interactions Sort By:

Contraindicated (49)

• amitriptyline
  amitriptyline and sotalol both increase QTc interval. Contraindicated.
• amoxapine
  amoxapine and sotalol both increase QTc interval. Contraindicated.
• artemether/lumefantrine
  artemether/lumefantrine and sotalol both increase QTc interval. Contraindicated.
• chlorpromazine
  chlorpromazine and sotalol both increase QTc interval. Contraindicated.
• clomipramine
  clomipramine and sotalol both increase QTc interval. Contraindicated.
• desipramine
  desipramine and sotalol both increase QTc interval. Contraindicated.
• disopyramide
  disopyramide and sotalol both increase QTc interval. Contraindicated.
• dofetilide
  dofetilide and sotalol both increase QTc interval. Contraindicated.sotalol, dofetilide. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Additive cardiac effects.
• doxepin
  doxepin and sotalol both increase QTc interval. Contraindicated.
• dronedarone
  dronedarone and sotalol both increase QTc interval. Contraindicated.
• droperidol
  droperidol and sotalol both increase QTc interval. Contraindicated.
• epinephrine
  epinephrine and sotalol both increase QTc interval. Contraindicated.
• epinephrine racemic
  epinephrine racemic and sotalol both increase QTc interval. Contraindicated.
• erythromycin base
  erythromycin base and sotalol both increase QTc interval. Contraindicated.
• erythromycin ethylsuccinate
  erythromycin ethylsuccinate and sotalol both increase QTc interval. Contraindicated.
• erythromycin lactobionate
  erythromycin lactobionate and sotalol both increase QTc interval. Contraindicated.
• erythromycin stearate
  erythromycin stearate and sotalol both increase QTc interval. Contraindicated.
• fingolimod
  fingolimod increases effects of sotalol by pharmacodynamic synergism. Contraindicated. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.fingolimod and sotalol both increase QTc interval. Contraindicated.
• fluphenazine
  fluphenazine and sotalol both increase QTc interval. Contraindicated.
• goserelin
  goserelin increases toxicity of sotalol by QTc interval. Contraindicated. Increases risk of torsades de pointes.
• haloperidol
  haloperidol and sotalol both increase QTc interval. Contraindicated.
• ibutilide
  ibutilide and sotalol both increase QTc interval. Contraindicated.
• imipramine
  imipramine and sotalol both increase QTc interval. Contraindicated.
• indapamide
  indapamide and sotalol both increase QTc interval. Contraindicated.
• ketoconazole
  ketoconazole and sotalol both increase QTc interval. Contraindicated.
• leuprolide
  leuprolide increases toxicity of sotalol by QTc interval. Contraindicated. Increases risk of torsades de pointes.
• levoketoconazole
  levoketoconazole and sotalol both increase QTc interval. Contraindicated.
• lofepramine
  lofepramine and sotalol both increase QTc interval. Contraindicated.
• lumefantrine
  lumefantrine and sotalol both increase QTc interval. Contraindicated.
• maprotiline
  maprotiline and sotalol both increase QTc interval. Contraindicated.
• moxifloxacin
  moxifloxacin and sotalol both increase QTc interval. Contraindicated.
• nilotinib
  nilotinib and sotalol both increase QTc interval. Contraindicated.
• nortriptyline
  nortriptyline and sotalol both increase QTc interval. Contraindicated.
• octreotide
  octreotide and sotalol both increase QTc interval. Contraindicated.
• octreotide (Antidote)
  octreotide (Antidote) and sotalol both increase QTc interval. Contraindicated.
• pentamidine
  pentamidine and sotalol both increase QTc interval. Contraindicated.
• perphenazine
  perphenazine and sotalol both increase QTc interval. Contraindicated.
• pimozide
  pimozide and sotalol both increase QTc interval. Contraindicated.
• procainamide
  procainamide and sotalol both increase QTc interval. Contraindicated.
• prochlorperazine
  prochlorperazine and sotalol both increase QTc interval. Contraindicated.
• promazine
  promazine and sotalol both increase QTc interval. Contraindicated.
• promethazine
  promethazine and sotalol both increase QTc interval. Contraindicated.
• protriptyline
  protriptyline and sotalol both increase QTc interval. Contraindicated.
• quinidine
  quinidine and sotalol both increase QTc interval. Contraindicated.
• thioridazine
  thioridazine and sotalol both increase QTc interval. Contraindicated.
• trazodone
  trazodone and sotalol both increase QTc interval. Contraindicated.
• trifluoperazine
  trifluoperazine and sotalol both increase QTc interval. Contraindicated.
• trimipramine
  trimipramine and sotalol both increase QTc interval. Contraindicated.
• ziprasidone
  sotalol and ziprasidone both increase QTc interval. Contraindicated.

Serious (114)

• acebutolol
  acebutolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• adagrasib
  adagrasib, sotalol. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
• alfuzosin
  alfuzosin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• amiodarone
  amiodarone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• amisulpride
  amisulpride and sotalol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
• anagrelide
  anagrelide and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• apomorphine
  apomorphine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• aripiprazole
  aripiprazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• arsenic trioxide
  arsenic trioxide and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• artemether
  artemether and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• asenapine
  asenapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• asenapine transdermal
  asenapine transdermal and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• atenolol
  atenolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• atomoxetine
  atomoxetine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• betaxolol
  betaxolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• bisoprolol
  bisoprolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• buprenorphine
  buprenorphine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• buprenorphine buccal
  buprenorphine buccal and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• buprenorphine subdermal implant
  buprenorphine subdermal implant and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• buprenorphine transdermal
  buprenorphine transdermal and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• buprenorphine, long-acting injection
  buprenorphine, long-acting injection and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• carvedilol
  carvedilol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• celiprolol
  celiprolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• ceritinib
  ceritinib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• clarithromycin
  clarithromycin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• clonidine
  clonidine, sotalol. Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.
• clozapine
  clozapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• dasatinib
  dasatinib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• degarelix
  degarelix and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• desflurane
  desflurane and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• digoxin
  digoxin, sotalol. Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.
• diltiazem
  diltiazem, sotalol. Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.
• dolasetron
  dolasetron and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• donepezil
  donepezil and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• efavirenz
  efavirenz and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• eliglustat
  eliglustat and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• encorafenib
  encorafenib and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid with drugs known to prolong QT interval.
• entrectinib
  sotalol and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
• eribulin
  eribulin and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.
• escitalopram
  escitalopram and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• esmolol
  esmolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• fexinidazole
  fexinidazole, sotalol. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to induce bradycardia. .fexinidazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.
• flecainide
  flecainide and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• fluconazole
  fluconazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Avoid combination if possible. Potential for increased risk of QT prolongation.
• fluoxetine
  fluoxetine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• fluvoxamine
  fluvoxamine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• formoterol
  formoterol and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Drugs known to prolong the QTc interval may potentiate the cardiovascular effects of formoterol.sotalol and formoterol both increase QTc interval. Avoid or Use Alternate Drug. Drugs known to prolong the QTc interval may potentiate the cardiovascular effects of formoterol.
• foscarnet
  foscarnet and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• gadobenate
  gadobenate and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• gemifloxacin
  gemifloxacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• givinostat
  sotalol and givinostat both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms.
• glasdegib
  sotalol and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
• granisetron
  granisetron and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• histrelin
  histrelin increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.
• hydroxychloroquine sulfate
  hydroxychloroquine sulfate and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• hydroxyzine
  hydroxyzine increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.
• iloperidone
  iloperidone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• inotuzumab
  inotuzumab and sotalol both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
• iobenguane I 131
  sotalol will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.
• isoflurane
  isoflurane and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• ivosidenib
  ivosidenib and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
• labetalol
  labetalol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• lapatinib
  lapatinib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• lefamulin
  lefamulin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• levofloxacin
  levofloxacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• lithium
  lithium and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• lofexidine
  lofexidine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.
• macimorelin
  macimorelin and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
• mavacamten
  sotalol, mavacamten. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility.
• mefloquine
  mefloquine increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
• methadone
  methadone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• metoprolol
  metoprolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• mirtazapine
  mirtazapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• nadolol
  nadolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• nebivolol
  nebivolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• ofloxacin
  ofloxacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• olanzapine
  olanzapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• ondansetron
  ondansetron and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
• oxaliplatin
  oxaliplatin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• paliperidone
  paliperidone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• panobinostat
  sotalol and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
• paroxetine
  paroxetine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• penbutolol
  penbutolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• pimavanserin
  pimavanserin and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Coadministration may increase the risk of QT prolongation and cardiac arrhythmia.
• pindolol
  pindolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• pitolisant
  sotalol and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
• posaconazole
  posaconazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• primaquine
  primaquine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• propranolol
  propranolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• ranolazine
  ranolazine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• ribociclib
  ribociclib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• risperidone
  risperidone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• rivastigmine
  sotalol increases toxicity of rivastigmine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive bradycardia effect may result in syncope.
• sevoflurane
  sevoflurane and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• siponimod
  siponimod, sotalol. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Because of the potential additive effects on heart rate, siponimod should generally not be initiated in patients taking QT prolonging drugs with known arrhythmogenic properties, heart rate lowering calcium channel blockers, or other drugs that may decrease heart rate. If treatment considered, obtain cardiology consult regarding switching to non-heart-rate lowering drugs or appropriate monitoring for treatment initiation.
• solifenacin
  solifenacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• sulfamethoxazole
  sulfamethoxazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• sunitinib
  sunitinib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• tacrolimus
  tacrolimus and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• telavancin
  sotalol and telavancin both increase QTc interval. Avoid or Use Alternate Drug.
• tetrabenazine
  tetrabenazine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
• timolol
  sotalol and timolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.
• toremifene
  sotalol and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
• trimethoprim
  sotalol and trimethoprim both increase QTc interval. Avoid or Use Alternate Drug.
• triptorelin
  triptorelin increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.
• tropisetron
  sotalol and tropisetron both increase QTc interval. Avoid or Use Alternate Drug.
• umeclidinium bromide/vilanterol inhaled
  sotalol increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.sotalol, umeclidinium bromide/vilanterol inhaled. pharmacodynamic antagonism. Avoid or Use Alternate Drug. If a beta-blocker must be used in patients with COPD taking a beta-agonist, consider using a beta-blocker that is beta-1 selective .
• vandetanib
  sotalol, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
• vemurafenib
  vemurafenib and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.
• venlafaxine
  sotalol and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug.
• verapamil
  verapamil, sotalol. Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.
• vilanterol/fluticasone furoate inhaled
  sotalol, vilanterol/fluticasone furoate inhaled. pharmacodynamic antagonism. Avoid or Use Alternate Drug. If a beta-blocker must be used in patients with COPD taking a beta-agonist, consider using a beta-blocker that is beta-1 selective .sotalol increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
• voriconazole
  sotalol and voriconazole both increase QTc interval. Avoid or Use Alternate Drug.
• vorinostat
  vorinostat and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

Monitor Closely (213)

• acebutolol
  acebutolol and sotalol both increase serum potassium. Use Caution/Monitor.
• aceclofenac
  sotalol and aceclofenac both increase serum potassium. Use Caution/Monitor.aceclofenac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• acemetacin
  sotalol and acemetacin both increase serum potassium. Use Caution/Monitor.acemetacin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• albuterol
  sotalol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor.albuterol and sotalol both increase QTc interval. Use Caution/Monitor.
• aldesleukin
  aldesleukin increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
• alfuzosin
  alfuzosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.sotalol and alfuzosin both increase QTc interval. Use Caution/Monitor.
• aluminum hydroxide
  aluminum hydroxide decreases levels of sotalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
• amifostine
  amifostine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.
• amiloride
  sotalol and amiloride both increase serum potassium. Modify Therapy/Monitor Closely.
• amiodarone
  amiodarone, sotalol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of cardiotoxicity with bradycardia.
• amlodipine
  sotalol and amlodipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• amobarbital
  amobarbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of amobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
• arformoterol
  sotalol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor.arformoterol and sotalol both increase QTc interval. Use Caution/Monitor.
• asenapine
  asenapine and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• aspirin
  sotalol and aspirin both increase serum potassium. Use Caution/Monitor.aspirin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• aspirin rectal
  sotalol and aspirin rectal both increase serum potassium. Use Caution/Monitor.aspirin rectal decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• aspirin/citric acid/sodium bicarbonate
  aspirin/citric acid/sodium bicarbonate decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.sotalol and aspirin/citric acid/sodium bicarbonate both increase serum potassium. Use Caution/Monitor.
• atenolol
  atenolol and sotalol both increase serum potassium. Use Caution/Monitor.
• avanafil
  avanafil increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
• azithromycin
  azithromycin and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.
• bedaquiline
  sotalol and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
• bendroflumethiazide
  sotalol increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• benzgalantamine
  benzgalantamine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Galantamine, an acetylcholinesterase inhibitor, has vagotonic effects on the SA and AV nodes, leading to bradycardia. Consider consulting a cardiolist before initiating other drugs that may cause bradycardia.
• betaxolol
  betaxolol and sotalol both increase serum potassium. Use Caution/Monitor.
• bismuth subsalicylate
  bismuth subsalicylate, sotalol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension.
• bisoprolol
  bisoprolol and sotalol both increase serum potassium. Use Caution/Monitor.
• bretylium
  sotalol, bretylium. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension.
• bumetanide
  sotalol increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• butabarbital
  butabarbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butabarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
• butalbital
  butalbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butalbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
• calcium acetate
  calcium acetate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.
• calcium carbonate
  calcium carbonate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.calcium carbonate decreases levels of sotalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
• calcium chloride
  calcium chloride decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.
• calcium citrate
  calcium citrate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.
• calcium gluconate
  calcium gluconate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.
• candesartan
  candesartan and sotalol both increase serum potassium. Use Caution/Monitor.sotalol, candesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
• carbenoxolone
  sotalol increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• carbidopa
  carbidopa increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.
• carvedilol
  carvedilol and sotalol both increase serum potassium. Use Caution/Monitor.
• celecoxib
  sotalol and celecoxib both increase serum potassium. Use Caution/Monitor.celecoxib decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• celiprolol
  celiprolol and sotalol both increase serum potassium. Use Caution/Monitor.
• chloroquine
  chloroquine and sotalol both increase QTc interval. Use Caution/Monitor.
• chlorothiazide
  sotalol increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• chlorthalidone
  sotalol increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• choline magnesium trisalicylate
  sotalol and choline magnesium trisalicylate both increase serum potassium. Use Caution/Monitor.choline magnesium trisalicylate decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• ciprofloxacin
  ciprofloxacin and sotalol both increase QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.
• citalopram
  sotalol and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
• clevidipine
  sotalol and clevidipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• clonidine
  sotalol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.
• crizotinib
  crizotinib and sotalol both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
• cyclopenthiazide
  sotalol increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• dabrafenib
  dabrafenib and sotalol both increase QTc interval. Use Caution/Monitor.
• dasiglucagon
  sotalol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP.
• desflurane
  desflurane, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
• deutetrabenazine
  sotalol and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
• diclofenac
  sotalol and diclofenac both increase serum potassium. Use Caution/Monitor.diclofenac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• diflunisal
  sotalol and diflunisal both increase serum potassium. Use Caution/Monitor.diflunisal decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• digoxin
  sotalol and digoxin both increase serum potassium. Use Caution/Monitor.sotalol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.
• diltiazem
  sotalol and diltiazem both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• dobutamine
  sotalol increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of dobutamine by pharmacodynamic antagonism. Use Caution/Monitor.
• dopexamine
  sotalol increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of dopexamine by pharmacodynamic antagonism. Use Caution/Monitor.
• doxazosin
  doxazosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of doxozosin may be enhanced.
• drospirenone
  sotalol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.
• ephedrine
  sotalol increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of ephedrine by pharmacodynamic antagonism. Use Caution/Monitor.
• epinephrine
  sotalol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor.
• epinephrine inhaled
  sotalol decreases effects of epinephrine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. Beta2-adrenergic blockers may may inhibit bronchodilatory effects of epinephrine.
• epinephrine intranasal
  epinephrine intranasal, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for cardiac arrhythmias if epinephrine is coadministered with cardiac glycosides, diuretics, or antiarrhythmic drugs. .sotalol decreases effects of epinephrine intranasal by pharmacodynamic antagonism. Use Caution/Monitor.
• epinephrine racemic
  sotalol increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor.
• eprosartan
  eprosartan and sotalol both increase serum potassium. Use Caution/Monitor.sotalol, eprosartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
• esmolol
  esmolol and sotalol both increase serum potassium. Use Caution/Monitor.
• ethacrynic acid
  sotalol increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• ether
  sotalol, ether. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both beta blockers and ether depress the myocardium; consider lowering beta blocker dose if ether used for anesthesia.
• etodolac
  sotalol and etodolac both increase serum potassium. Use Caution/Monitor.etodolac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• etomidate
  etomidate, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
• etrasimod
  etrasimod, sotalol. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Transient decrease in heart rate and AV conduction delays may occur when initiating etrasimod. Owing to potential of additive effect on heart rate, etrasimod may increase risk of QT prolongation and Torsades de Pointes when coadministered with Class Ia or Class III antiarrhythmic drugs, or other drugs that prolong the QT interval. .
• ezogabine
  ezogabine, sotalol. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
• felodipine
  sotalol and felodipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• fenbufen
  sotalol and fenbufen both increase serum potassium. Use Caution/Monitor.
• fenoprofen
  sotalol and fenoprofen both increase serum potassium. Use Caution/Monitor.fenoprofen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• floxuridine
  floxuridine and sotalol both increase QTc interval. Use Caution/Monitor.
• flurbiprofen
  sotalol and flurbiprofen both increase serum potassium. Use Caution/Monitor.flurbiprofen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• formoterol
  sotalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.
• fostemsavir
  sotalol and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
• furosemide
  sotalol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• galantamine
  galantamine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Galantamine, an acetylcholinesterase inhibitor, has vagotonic effects on the SA and AV nodes, leading to bradycardia. Consider consulting a cardiolist before initiating other drugs that may cause bradycardia.
• gemtuzumab
  sotalol and gemtuzumab both increase QTc interval. Use Caution/Monitor.
• gentamicin
  sotalol increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• gepirone
  gepirone and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.
• gilteritinib
  gilteritinib and sotalol both increase QTc interval. Use Caution/Monitor.
• glucagon
  glucagon decreases toxicity of sotalol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure.
• glucagon intranasal
  glucagon intranasal decreases toxicity of sotalol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure.
• hawthorn
  hawthorn increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor.
• hydralazine
  hydralazine increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.
• hydrochlorothiazide
  sotalol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• ibuprofen
  sotalol and ibuprofen both increase serum potassium. Use Caution/Monitor.ibuprofen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• ibuprofen IV
  ibuprofen IV decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.sotalol and ibuprofen IV both increase serum potassium. Use Caution/Monitor.
• iloprost
  iloprost, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. When administering iloprost IV, consider temporary discontinuation of concomitant vasodilators or other medications that reduce blood pressure to mitigate potential additive hypotensive effects. If hypotension persists despite discontinuing other antihypertensives and fluid resuscitation, consider iloprost dose reduction or discontinuation.
• indacaterol, inhaled
  indacaterol, inhaled, sotalol. Other (see comment). Use Caution/Monitor. Comment: Beta-blockers and indacaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.indacaterol, inhaled, sotalol. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
• indapamide
  sotalol increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• indomethacin
  sotalol and indomethacin both increase serum potassium. Use Caution/Monitor.indomethacin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• insulin degludec
  sotalol, insulin degludec. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).
• insulin degludec/insulin aspart
  sotalol, insulin degludec/insulin aspart. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).
• insulin inhaled
  sotalol, insulin inhaled. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).
• irbesartan
  irbesartan and sotalol both increase serum potassium. Use Caution/Monitor.sotalol, irbesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
• isoproterenol
  sotalol increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of isoproterenol by pharmacodynamic antagonism. Use Caution/Monitor.
• isradipine
  sotalol and isradipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• itraconazole
  itraconazole and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.
• ivabradine
  ivabradine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Most patients receiving ivabradine will also be treated with a beta-blocker. The risk of bradycardia increases with coadministration of drugs that slow heart rate (eg, digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine with other negative chronotropes.
• ketamine
  ketamine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
• ketoprofen
  sotalol and ketoprofen both increase serum potassium. Use Caution/Monitor.ketoprofen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• ketorolac
  sotalol and ketorolac both increase serum potassium. Use Caution/Monitor.ketorolac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• ketorolac intranasal
  sotalol and ketorolac intranasal both increase serum potassium. Use Caution/Monitor.ketorolac intranasal decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• labetalol
  labetalol and sotalol both increase serum potassium. Use Caution/Monitor.
• lasmiditan
  sotalol increases effects of lasmiditan by pharmacodynamic synergism. Use Caution/Monitor. Lasmiditan has been associated with a lowering of heart rate (HR). In a drug interaction study, addition of a single 200-mg dose of lasmiditan to propranolol decreased HR by an additional 5 bpm compared to propranolol alone, for a mean maximum of 19 bpm.
• lenvatinib
  sotalol and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
• levalbuterol
  sotalol increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of levalbuterol by pharmacodynamic antagonism. Use Caution/Monitor.
• levodopa
  levodopa increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.
• lofexidine
  sotalol and lofexidine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended.
• lornoxicam
  sotalol and lornoxicam both increase serum potassium. Use Caution/Monitor.lornoxicam decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• losartan
  losartan and sotalol both increase serum potassium. Use Caution/Monitor.sotalol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
• mavorixafor
  mavorixafor and sotalol both increase QTc interval. Modify Therapy/Monitor Closely. Mavorixafor causes concentration-dependent QTc prolongation. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required.
• meclofenamate
  meclofenamate decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.sotalol and meclofenamate both increase serum potassium. Use Caution/Monitor.
• mefenamic acid
  sotalol and mefenamic acid both increase serum potassium. Use Caution/Monitor.mefenamic acid decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• mefloquine
  mefloquine increases levels of sotalol by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia.
• meloxicam
  sotalol and meloxicam both increase serum potassium. Use Caution/Monitor.meloxicam decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• metaproterenol
  sotalol increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of metaproterenol by pharmacodynamic antagonism. Use Caution/Monitor.
• methyclothiazide
  sotalol increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
• methylphenidate
  methylphenidate will decrease the level or effect of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.
• methylphenidate transdermal
  methylphenidate transdermal decreases effects of sotalol by anti-hypertensive channel blocking. Use Caution/Monitor.
• metolazone
  sotalol increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• metoprolol
  metoprolol and sotalol both increase serum potassium. Use Caution/Monitor.
• mifepristone
  mifepristone, sotalol. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.
• moxisylyte
  moxisylyte and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• nabumetone
  sotalol and nabumetone both increase serum potassium. Use Caution/Monitor.nabumetone decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• nadolol
  nadolol and sotalol both increase serum potassium. Use Caution/Monitor.
• naproxen
  sotalol and naproxen both increase serum potassium. Use Caution/Monitor.naproxen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• nebivolol
  nebivolol and sotalol both increase serum potassium. Use Caution/Monitor.
• nicardipine
  sotalol and nicardipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• nifedipine
  sotalol and nifedipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• nisoldipine
  sotalol and nisoldipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• nitroglycerin rectal
  nitroglycerin rectal, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers blunt the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effects. If beta-blockers are used with nitroglycerin in patients with angina pectoris, additional hypotensive effects may occur.
• norepinephrine
  sotalol increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of norepinephrine by pharmacodynamic antagonism. Use Caution/Monitor.
• olanzapine/samidorphan
  olanzapine/samidorphan increases effects of sotalol by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Monitor blood pressure and reduce antihypertensive drug dosage in accordance with its product labeling.
• olmesartan
  olmesartan and sotalol both increase serum potassium. Use Caution/Monitor.sotalol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
• olodaterol inhaled
  sotalol, olodaterol inhaled. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor. Beta-blockers and olodaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.sotalol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
• osilodrostat
  osilodrostat and sotalol both increase QTc interval. Use Caution/Monitor.
• osimertinib
  osimertinib and sotalol both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
• oxaliplatin
  oxaliplatin will increase the level or effect of sotalol by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
• oxaprozin
  sotalol and oxaprozin both increase serum potassium. Use Caution/Monitor.oxaprozin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• oxymetazoline intranasal
  sotalol increases effects of oxymetazoline intranasal by pharmacodynamic synergism. Use Caution/Monitor. When beta-2 receptors are antagonized by nonselective beta blockers, alpha1 vasoconstriction may be unopposed, thus increasing hypertensive effect. When oxymetazoline is combined with intranasal tetracaine for dental anesthesia, avoid or use an alternant anesthetic in patients taking nonselective beta blockers.
• oxymetazoline topical
  oxymetazoline topical increases and sotalol decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• ozanimod
  ozanimod and sotalol both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
• parecoxib
  sotalol and parecoxib both increase serum potassium. Use Caution/Monitor.parecoxib decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• pasireotide
  sotalol and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
• pazopanib
  pazopanib and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.
• penbutolol
  penbutolol and sotalol both increase serum potassium. Use Caution/Monitor.
• pentobarbital
  pentobarbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of pentobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
• phenobarbital
  phenobarbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of phenobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
• phenoxybenzamine
  phenoxybenzamine and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• phentolamine
  phentolamine and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• pindolol
  pindolol and sotalol both increase serum potassium. Use Caution/Monitor.
• pirbuterol
  sotalol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of pirbuterol by pharmacodynamic antagonism. Use Caution/Monitor.
• piroxicam
  sotalol and piroxicam both increase serum potassium. Use Caution/Monitor.piroxicam decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• ponesimod
  ponesimod and sotalol both increase pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers may have additive effects on lowering HR. Consider resting HR before initiating ponesimod in patients on stable dose of beta-blocker. Refer to the ponesimod prescribing information for more dosing information.ponesimod, sotalol. Either increases effects of the other by QTc interval. Use Caution/Monitor. Consult cardiologist if considering treatment. Class III (eg, amiodarone, dofetilide, sotalol) anti-arrhythmic drugs have been associated with cases of torsades de pointes in patients with bradycardia.
• potassium acid phosphate
  sotalol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.
• potassium chloride
  sotalol and potassium chloride both increase serum potassium. Modify Therapy/Monitor Closely.
• potassium citrate
  sotalol and potassium citrate both increase serum potassium. Modify Therapy/Monitor Closely.
• prazosin
  prazosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of prazosin may be enhanced.
• primidone
  primidone decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of primidone. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.
• promazine
  promazine, sotalol. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Increased risk of ventricular arrhythmia.
• propofol
  propofol, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
• propranolol
  propranolol and sotalol both increase serum potassium. Use Caution/Monitor.
• quetiapine
  quetiapine, sotalol. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.
• quinine
  sotalol and quinine both increase QTc interval. Use Caution/Monitor.
• quizartinib
  quizartinib, sotalol. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
• rilpivirine
  rilpivirine increases toxicity of sotalol by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.
• romidepsin
  romidepsin and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.
• sacubitril/valsartan
  sacubitril/valsartan and sotalol both increase serum potassium. Use Caution/Monitor.sotalol, sacubitril/valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
• salicylates (non-asa)
  sotalol and salicylates (non-asa) both increase serum potassium. Use Caution/Monitor.salicylates (non-asa) decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• salmeterol
  sotalol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.
• salsalate
  sotalol and salsalate both increase serum potassium. Use Caution/Monitor.salsalate decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• selpercatinib
  selpercatinib and sotalol both increase QTc interval. Use Caution/Monitor.
• sertraline
  sertraline and sotalol both increase QTc interval. Use Caution/Monitor.
• sevelamer
  sevelamer decreases levels of sotalol by increasing elimination. Use Caution/Monitor.
• sevoflurane
  sevoflurane, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
• sildenafil
  sotalol increases effects of sildenafil by additive vasodilation. Use Caution/Monitor. Sildenafil has systemic vasodilatory properties and may further lower blood pressure in patients taking antihypertensive medications. Monitor blood pressure response to sildenafil in patients receiving concurrent blood pressure lowering therapy.
• silodosin
  silodosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Increased risk of dizziness and orthostatic hypotension when silodosin is administered concurrently with antihypertensives.
• siponimod
  siponimod, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Caution when siponimod is initiated in patients receiving beta-blocker treatment because of additive effects on lowering heart rate. Temporary interruption of beta-blocker may be needed before initiating siponimod. Beta-blocker treatment can be initiated in patients receiving stable doses of siponimod.
• sodium bicarbonate
  sodium bicarbonate decreases levels of sotalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
• sodium citrate/citric acid
  sodium citrate/citric acid decreases levels of sotalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
• sodium sulfate/?magnesium sulfate/potassium chloride
  sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of sotalol by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .
• sodium sulfate/potassium sulfate/magnesium sulfate
  sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of sotalol by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .
• sorafenib
  sorafenib and sotalol both increase QTc interval. Use Caution/Monitor.
• spironolactone
  sotalol and spironolactone both increase serum potassium. Modify Therapy/Monitor Closely.
• succinylcholine
  sotalol and succinylcholine both increase serum potassium. Use Caution/Monitor.
• sulfasalazine
  sotalol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• sulindac
  sotalol and sulindac both increase serum potassium. Use Caution/Monitor.sulindac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• tadalafil
  tadalafil increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
• telmisartan
  telmisartan and sotalol both increase serum potassium. Use Caution/Monitor.sotalol, telmisartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
• terazosin
  terazosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Additive hypotensive effects may occur when terazosin is used in combination with sotalol.
• terbutaline
  sotalol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sotalol decreases effects of terbutaline by pharmacodynamic antagonism. Use Caution/Monitor.
• theophylline
  sotalol, theophylline. Other (see comment). Use Caution/Monitor. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.
• timolol
  sotalol and timolol both increase serum potassium. Use Caution/Monitor.
• tolfenamic acid
  sotalol and tolfenamic acid both increase serum potassium. Use Caution/Monitor.tolfenamic acid decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• tolmetin
  sotalol and tolmetin both increase serum potassium. Use Caution/Monitor.tolmetin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
• tolvaptan
  sotalol and tolvaptan both increase serum potassium. Use Caution/Monitor.
• torsemide
  sotalol increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.
• triamterene
  sotalol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.
• triclabendazole
  triclabendazole and sotalol both increase QTc interval. Use Caution/Monitor.
• valsartan
  valsartan and sotalol both increase serum potassium. Use Caution/Monitor.sotalol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
• verapamil
  sotalol and verapamil both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
• voclosporin
  voclosporin, sotalol. Either increases effects of the other by QTc interval. Use Caution/Monitor.
• xipamide
  xipamide increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor.

Minor (29)

• adenosine
  sotalol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.

• agrimony
  agrimony increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• benazepril
  sotalol, benazepril. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May increase risk of hypotension.

• brimonidine
  brimonidine increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• cevimeline
  cevimeline increases effects of sotalol by unspecified interaction mechanism. Minor/Significance Unknown.

• cocaine topical
  sotalol increases effects of cocaine topical by pharmacodynamic synergism. Minor/Significance Unknown. Risk of angina.

• cornsilk
  cornsilk increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• dihydroergotamine
  dihydroergotamine, sotalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm.

• dihydroergotamine intranasal
  dihydroergotamine intranasal, sotalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm.

• dipyridamole
  dipyridamole, sotalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of bradycardia.

• escitalopram
  escitalopram increases levels of sotalol by decreasing metabolism. Minor/Significance Unknown.

• fenoldopam
  fenoldopam increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

• forskolin
  forskolin increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• guanfacine
  sotalol, guanfacine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.

• imaging agents (gadolinium)
  sotalol, imaging agents (gadolinium). Mechanism: unknown. Minor/Significance Unknown. Increased risk of anaphylaxis from contrast media.

• levobetaxolol
  levobetaxolol increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• lily of the valley
  sotalol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

• maitake
  maitake increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• metipranolol ophthalmic
  metipranolol ophthalmic increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• neostigmine
  sotalol, neostigmine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia.

• noni juice
  sotalol and noni juice both increase serum potassium. Minor/Significance Unknown.

• octacosanol
  octacosanol increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• physostigmine
  sotalol, physostigmine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia.

• pilocarpine
  pilocarpine increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• reishi
  reishi increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• shepherd's purse
  shepherd's purse, sotalol. Other (see comment). Minor/Significance Unknown. Comment: Theoretically, shepherd's purse may interfere with BP control.

• tizanidine
  tizanidine increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.

• treprostinil
  treprostinil increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• yohimbe
  sotalol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

• acebutolol
  Monitor Closely (1)acebutolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)acebutolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• aceclofenac
  Monitor Closely (2)aceclofenac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and aceclofenac both increase serum potassium. Use Caution/Monitor.

• acemetacin
  Monitor Closely (2)acemetacin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and acemetacin both increase serum potassium. Use Caution/Monitor.

• adagrasib
  Serious - Use Alternative (1)adagrasib, sotalol. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.

• adenosine
  Minor (1)sotalol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.

• agrimony
  Minor (1)agrimony increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• albuterol
  Monitor Closely (3)sotalol decreases effects of albuterol by pharmacodynamic antagonism. Use Caution/Monitor.
  albuterol and sotalol both increase QTc interval. Use Caution/Monitor.
  sotalol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• aldesleukin
  Monitor Closely (1)aldesleukin increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

• alfuzosin
  Monitor Closely (2)sotalol and alfuzosin both increase QTc interval. Use Caution/Monitor.
  alfuzosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.Serious - Use Alternative (1)alfuzosin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• aluminum hydroxide
  Monitor Closely (1)aluminum hydroxide decreases levels of sotalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

• amifostine
  Monitor Closely (1)amifostine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.

• amiloride
  Monitor Closely (1)sotalol and amiloride both increase serum potassium. Modify Therapy/Monitor Closely.

• amiodarone
  Monitor Closely (1)amiodarone, sotalol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of cardiotoxicity with bradycardia.Serious - Use Alternative (1)amiodarone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• amisulpride
  Serious - Use Alternative (1)amisulpride and sotalol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

• amitriptyline
  Contraindicated (1)amitriptyline and sotalol both increase QTc interval. Contraindicated.

• amlodipine
  Monitor Closely (1)sotalol and amlodipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• amobarbital
  Monitor Closely (1)amobarbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of amobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

• amoxapine
  Contraindicated (1)amoxapine and sotalol both increase QTc interval. Contraindicated.

• anagrelide
  Serious - Use Alternative (1)anagrelide and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• apomorphine
  Serious - Use Alternative (1)apomorphine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• arformoterol
  Monitor Closely (3)sotalol decreases effects of arformoterol by pharmacodynamic antagonism. Use Caution/Monitor.
  arformoterol and sotalol both increase QTc interval. Use Caution/Monitor.
  sotalol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• aripiprazole
  Serious - Use Alternative (1)aripiprazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• arsenic trioxide
  Serious - Use Alternative (1)arsenic trioxide and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• artemether
  Serious - Use Alternative (1)artemether and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• artemether/lumefantrine
  Contraindicated (1)artemether/lumefantrine and sotalol both increase QTc interval. Contraindicated.

• asenapine
  Monitor Closely (1)asenapine and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)asenapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• asenapine transdermal
  Serious - Use Alternative (1)asenapine transdermal and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• aspirin
  Monitor Closely (2)aspirin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and aspirin both increase serum potassium. Use Caution/Monitor.

• aspirin rectal
  Monitor Closely (2)aspirin rectal decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and aspirin rectal both increase serum potassium. Use Caution/Monitor.

• aspirin/citric acid/sodium bicarbonate
  Monitor Closely (2)aspirin/citric acid/sodium bicarbonate decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and aspirin/citric acid/sodium bicarbonate both increase serum potassium. Use Caution/Monitor.

• atenolol
  Monitor Closely (1)atenolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)atenolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• atomoxetine
  Serious - Use Alternative (1)atomoxetine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• avanafil
  Monitor Closely (1)avanafil increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

• azithromycin
  Monitor Closely (1)azithromycin and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.

• bedaquiline
  Monitor Closely (1)sotalol and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely

• benazepril
  Minor (1)sotalol, benazepril. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May increase risk of hypotension.

• bendroflumethiazide
  Monitor Closely (1)sotalol increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• benzgalantamine
  Monitor Closely (1)benzgalantamine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Galantamine, an acetylcholinesterase inhibitor, has vagotonic effects on the SA and AV nodes, leading to bradycardia. Consider consulting a cardiolist before initiating other drugs that may cause bradycardia.

• betaxolol
  Monitor Closely (1)betaxolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)betaxolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• bismuth subsalicylate
  Monitor Closely (1)bismuth subsalicylate, sotalol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension.

• bisoprolol
  Monitor Closely (1)bisoprolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)bisoprolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• bretylium
  Monitor Closely (1)sotalol, bretylium. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension.

• brimonidine
  Minor (1)brimonidine increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• bumetanide
  Monitor Closely (1)sotalol increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• buprenorphine
  Serious - Use Alternative (1)buprenorphine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine buccal
  Serious - Use Alternative (1)buprenorphine buccal and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine subdermal implant
  Serious - Use Alternative (1)buprenorphine subdermal implant and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine transdermal
  Serious - Use Alternative (1)buprenorphine transdermal and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• buprenorphine, long-acting injection
  Serious - Use Alternative (1)buprenorphine, long-acting injection and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• butabarbital
  Monitor Closely (1)butabarbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butabarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

• butalbital
  Monitor Closely (1)butalbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butalbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

• calcium acetate
  Monitor Closely (1)calcium acetate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.

• calcium carbonate
  Monitor Closely (2)calcium carbonate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.
  calcium carbonate decreases levels of sotalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

• calcium chloride
  Monitor Closely (1)calcium chloride decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.

• calcium citrate
  Monitor Closely (1)calcium citrate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.

• calcium gluconate
  Monitor Closely (1)calcium gluconate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.

• candesartan
  Monitor Closely (2)sotalol, candesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
  candesartan and sotalol both increase serum potassium. Use Caution/Monitor.

• carbenoxolone
  Monitor Closely (1)sotalol increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• carbidopa
  Monitor Closely (1)carbidopa increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.

• carvedilol
  Monitor Closely (1)carvedilol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)carvedilol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• celecoxib
  Monitor Closely (2)celecoxib decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and celecoxib both increase serum potassium. Use Caution/Monitor.

• celiprolol
  Monitor Closely (1)celiprolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)celiprolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• ceritinib
  Serious - Use Alternative (1)ceritinib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• cevimeline
  Minor (1)cevimeline increases effects of sotalol by unspecified interaction mechanism. Minor/Significance Unknown.

• chloroquine
  Monitor Closely (1)chloroquine and sotalol both increase QTc interval. Use Caution/Monitor.

• chlorothiazide
  Monitor Closely (1)sotalol increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• chlorpromazine
  Contraindicated (1)chlorpromazine and sotalol both increase QTc interval. Contraindicated.

• chlorthalidone
  Monitor Closely (1)sotalol increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• choline magnesium trisalicylate
  Monitor Closely (2)choline magnesium trisalicylate decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and choline magnesium trisalicylate both increase serum potassium. Use Caution/Monitor.

• ciprofloxacin
  Monitor Closely (1)ciprofloxacin and sotalol both increase QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.

• citalopram
  Monitor Closely (1)sotalol and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

• clarithromycin
  Serious - Use Alternative (1)clarithromycin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• clevidipine
  Monitor Closely (1)sotalol and clevidipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• clomipramine
  Contraindicated (1)clomipramine and sotalol both increase QTc interval. Contraindicated.

• clonidine
  Monitor Closely (1)sotalol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.Serious - Use Alternative (1)clonidine, sotalol. Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.

• clozapine
  Serious - Use Alternative (1)clozapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• cocaine topical
  Minor (1)sotalol increases effects of cocaine topical by pharmacodynamic synergism. Minor/Significance Unknown. Risk of angina.

• cornsilk
  Minor (1)cornsilk increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• crizotinib
  Monitor Closely (1)crizotinib and sotalol both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

• cyclopenthiazide
  Monitor Closely (1)sotalol increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• dabrafenib
  Monitor Closely (1)dabrafenib and sotalol both increase QTc interval. Use Caution/Monitor.

• dasatinib
  Serious - Use Alternative (1)dasatinib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• dasiglucagon
  Monitor Closely (1)sotalol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP.

• degarelix
  Serious - Use Alternative (1)degarelix and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• desflurane
  Monitor Closely (1)desflurane, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.Serious - Use Alternative (1)desflurane and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• desipramine
  Contraindicated (1)desipramine and sotalol both increase QTc interval. Contraindicated.

• deutetrabenazine
  Monitor Closely (1)sotalol and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).

• diclofenac
  Monitor Closely (2)diclofenac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and diclofenac both increase serum potassium. Use Caution/Monitor.

• diflunisal
  Monitor Closely (2)diflunisal decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and diflunisal both increase serum potassium. Use Caution/Monitor.

• digoxin
  Monitor Closely (2)sotalol increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor. Enhanced bradycardia.
  sotalol and digoxin both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)digoxin, sotalol. Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.

• dihydroergotamine
  Minor (1)dihydroergotamine, sotalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm.

• dihydroergotamine intranasal
  Minor (1)dihydroergotamine intranasal, sotalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm.

• diltiazem
  Monitor Closely (1)sotalol and diltiazem both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)diltiazem, sotalol. Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.

• dipyridamole
  Minor (1)dipyridamole, sotalol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of bradycardia.

• disopyramide
  Contraindicated (1)disopyramide and sotalol both increase QTc interval. Contraindicated.

• dobutamine
  Monitor Closely (2)sotalol decreases effects of dobutamine by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• dofetilide
  Contraindicated (2)dofetilide and sotalol both increase QTc interval. Contraindicated.
  sotalol, dofetilide. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Additive cardiac effects.

• dolasetron
  Serious - Use Alternative (1)dolasetron and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• donepezil
  Serious - Use Alternative (1)donepezil and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• dopexamine
  Monitor Closely (2)sotalol decreases effects of dopexamine by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• doxazosin
  Monitor Closely (1)doxazosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of doxozosin may be enhanced.

• doxepin
  Contraindicated (1)doxepin and sotalol both increase QTc interval. Contraindicated.

• dronedarone
  Contraindicated (1)dronedarone and sotalol both increase QTc interval. Contraindicated.

• droperidol
  Contraindicated (1)droperidol and sotalol both increase QTc interval. Contraindicated.

• drospirenone
  Monitor Closely (1)sotalol and drospirenone both increase serum potassium. Modify Therapy/Monitor Closely.

• efavirenz
  Serious - Use Alternative (1)efavirenz and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• eliglustat
  Serious - Use Alternative (1)eliglustat and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• encorafenib
  Serious - Use Alternative (1)encorafenib and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid with drugs known to prolong QT interval.

• entrectinib
  Serious - Use Alternative (1)sotalol and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.

• ephedrine
  Monitor Closely (2)sotalol decreases effects of ephedrine by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• epinephrine
  Contraindicated (1)epinephrine and sotalol both increase QTc interval. Contraindicated.Monitor Closely (2)sotalol decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• epinephrine inhaled
  Monitor Closely (1)sotalol decreases effects of epinephrine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. Beta2-adrenergic blockers may may inhibit bronchodilatory effects of epinephrine.

• epinephrine intranasal
  Monitor Closely (2)epinephrine intranasal, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for cardiac arrhythmias if epinephrine is coadministered with cardiac glycosides, diuretics, or antiarrhythmic drugs. .
  sotalol decreases effects of epinephrine intranasal by pharmacodynamic antagonism. Use Caution/Monitor.

• epinephrine racemic
  Contraindicated (1)epinephrine racemic and sotalol both increase QTc interval. Contraindicated.Monitor Closely (2)sotalol decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• eprosartan
  Monitor Closely (2)sotalol, eprosartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
  eprosartan and sotalol both increase serum potassium. Use Caution/Monitor.

• eribulin
  Serious - Use Alternative (1)eribulin and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.

• erythromycin base
  Contraindicated (1)erythromycin base and sotalol both increase QTc interval. Contraindicated.

• erythromycin ethylsuccinate
  Contraindicated (1)erythromycin ethylsuccinate and sotalol both increase QTc interval. Contraindicated.

• erythromycin lactobionate
  Contraindicated (1)erythromycin lactobionate and sotalol both increase QTc interval. Contraindicated.

• erythromycin stearate
  Contraindicated (1)erythromycin stearate and sotalol both increase QTc interval. Contraindicated.

• escitalopram
  Serious - Use Alternative (1)escitalopram and sotalol both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)escitalopram increases levels of sotalol by decreasing metabolism. Minor/Significance Unknown.

• esmolol
  Monitor Closely (1)esmolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)esmolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• ethacrynic acid
  Monitor Closely (1)sotalol increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• ether
  Monitor Closely (1)sotalol, ether. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both beta blockers and ether depress the myocardium; consider lowering beta blocker dose if ether used for anesthesia.

• etodolac
  Monitor Closely (2)etodolac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and etodolac both increase serum potassium. Use Caution/Monitor.

• etomidate
  Monitor Closely (1)etomidate, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

• etrasimod
  Monitor Closely (1)etrasimod, sotalol. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Transient decrease in heart rate and AV conduction delays may occur when initiating etrasimod. Owing to potential of additive effect on heart rate, etrasimod may increase risk of QT prolongation and Torsades de Pointes when coadministered with Class Ia or Class III antiarrhythmic drugs, or other drugs that prolong the QT interval. .

• ezogabine
  Monitor Closely (1)ezogabine, sotalol. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.

• felodipine
  Monitor Closely (1)sotalol and felodipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• fenbufen
  Monitor Closely (1)sotalol and fenbufen both increase serum potassium. Use Caution/Monitor.

• fenoldopam
  Minor (1)fenoldopam increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.

• fenoprofen
  Monitor Closely (2)fenoprofen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and fenoprofen both increase serum potassium. Use Caution/Monitor.

• fexinidazole
  Serious - Use Alternative (2)fexinidazole, sotalol. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to induce bradycardia. .
  fexinidazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.

• fingolimod
  Contraindicated (2)fingolimod increases effects of sotalol by pharmacodynamic synergism. Contraindicated. Due to increased risk of bradycardia, AV block, and torsade de pointes, concomitant use is contraindicated.
  fingolimod and sotalol both increase QTc interval. Contraindicated.

• flecainide
  Serious - Use Alternative (1)flecainide and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• floxuridine
  Monitor Closely (1)floxuridine and sotalol both increase QTc interval. Use Caution/Monitor.

• fluconazole
  Serious - Use Alternative (1)fluconazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Avoid combination if possible. Potential for increased risk of QT prolongation.

• fluoxetine
  Serious - Use Alternative (1)fluoxetine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• fluphenazine
  Contraindicated (1)fluphenazine and sotalol both increase QTc interval. Contraindicated.

• flurbiprofen
  Monitor Closely (2)flurbiprofen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and flurbiprofen both increase serum potassium. Use Caution/Monitor.

• fluvoxamine
  Serious - Use Alternative (1)fluvoxamine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• formoterol
  Monitor Closely (2)sotalol decreases effects of formoterol by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)formoterol and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Drugs known to prolong the QTc interval may potentiate the cardiovascular effects of formoterol.
  sotalol and formoterol both increase QTc interval. Avoid or Use Alternate Drug. Drugs known to prolong the QTc interval may potentiate the cardiovascular effects of formoterol.

• forskolin
  Minor (1)forskolin increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• foscarnet
  Serious - Use Alternative (1)foscarnet and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• fostemsavir
  Monitor Closely (1)sotalol and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

• furosemide
  Monitor Closely (1)sotalol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• gadobenate
  Serious - Use Alternative (1)gadobenate and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• galantamine
  Monitor Closely (1)galantamine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Galantamine, an acetylcholinesterase inhibitor, has vagotonic effects on the SA and AV nodes, leading to bradycardia. Consider consulting a cardiolist before initiating other drugs that may cause bradycardia.

• gemifloxacin
  Serious - Use Alternative (1)gemifloxacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• gemtuzumab
  Monitor Closely (1)sotalol and gemtuzumab both increase QTc interval. Use Caution/Monitor.

• gentamicin
  Monitor Closely (1)sotalol increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• gepirone
  Monitor Closely (1)gepirone and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.

• gilteritinib
  Monitor Closely (1)gilteritinib and sotalol both increase QTc interval. Use Caution/Monitor.

• givinostat
  Serious - Use Alternative (1)sotalol and givinostat both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms.

• glasdegib
  Serious - Use Alternative (1)sotalol and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.

• glucagon
  Monitor Closely (1)glucagon decreases toxicity of sotalol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure.

• glucagon intranasal
  Monitor Closely (1)glucagon intranasal decreases toxicity of sotalol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure.

• goserelin
  Contraindicated (1)goserelin increases toxicity of sotalol by QTc interval. Contraindicated. Increases risk of torsades de pointes.

• granisetron
  Serious - Use Alternative (1)granisetron and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• guanfacine
  Minor (1)sotalol, guanfacine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.

• haloperidol
  Contraindicated (1)haloperidol and sotalol both increase QTc interval. Contraindicated.

• hawthorn
  Monitor Closely (1)hawthorn increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor.

• histrelin
  Serious - Use Alternative (1)histrelin increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

• hydralazine
  Monitor Closely (1)hydralazine increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects.

• hydrochlorothiazide
  Monitor Closely (1)sotalol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• hydroxychloroquine sulfate
  Serious - Use Alternative (1)hydroxychloroquine sulfate and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• hydroxyzine
  Serious - Use Alternative (1)hydroxyzine increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

• ibuprofen
  Monitor Closely (2)ibuprofen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and ibuprofen both increase serum potassium. Use Caution/Monitor.

• ibuprofen IV
  Monitor Closely (2)ibuprofen IV decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and ibuprofen IV both increase serum potassium. Use Caution/Monitor.

• ibutilide
  Contraindicated (1)ibutilide and sotalol both increase QTc interval. Contraindicated.

• iloperidone
  Serious - Use Alternative (1)iloperidone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• iloprost
  Monitor Closely (1)iloprost, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. When administering iloprost IV, consider temporary discontinuation of concomitant vasodilators or other medications that reduce blood pressure to mitigate potential additive hypotensive effects. If hypotension persists despite discontinuing other antihypertensives and fluid resuscitation, consider iloprost dose reduction or discontinuation.

• imaging agents (gadolinium)
  Minor (1)sotalol, imaging agents (gadolinium). Mechanism: unknown. Minor/Significance Unknown. Increased risk of anaphylaxis from contrast media.

• imipramine
  Contraindicated (1)imipramine and sotalol both increase QTc interval. Contraindicated.

• indacaterol, inhaled
  Monitor Closely (2)indacaterol, inhaled, sotalol. Other (see comment). Use Caution/Monitor. Comment: Beta-blockers and indacaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.
  indacaterol, inhaled, sotalol. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.

• indapamide
  Contraindicated (1)indapamide and sotalol both increase QTc interval. Contraindicated.Monitor Closely (1)sotalol increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• indomethacin
  Monitor Closely (2)indomethacin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and indomethacin both increase serum potassium. Use Caution/Monitor.

• inotuzumab
  Serious - Use Alternative (1)inotuzumab and sotalol both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.

• insulin degludec
  Monitor Closely (1)sotalol, insulin degludec. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).

• insulin degludec/insulin aspart
  Monitor Closely (1)sotalol, insulin degludec/insulin aspart. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).

• insulin inhaled
  Monitor Closely (1)sotalol, insulin inhaled. Other (see comment). Modify Therapy/Monitor Closely. Comment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited).

• iobenguane I 131
  Serious - Use Alternative (1)sotalol will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.

• irbesartan
  Monitor Closely (2)sotalol, irbesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
  irbesartan and sotalol both increase serum potassium. Use Caution/Monitor.

• isoflurane
  Serious - Use Alternative (1)isoflurane and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• isoproterenol
  Monitor Closely (2)sotalol decreases effects of isoproterenol by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• isradipine
  Monitor Closely (1)sotalol and isradipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• itraconazole
  Monitor Closely (1)itraconazole and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.

• ivabradine
  Monitor Closely (1)ivabradine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Most patients receiving ivabradine will also be treated with a beta-blocker. The risk of bradycardia increases with coadministration of drugs that slow heart rate (eg, digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine with other negative chronotropes.

• ivosidenib
  Serious - Use Alternative (1)ivosidenib and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.

• ketamine
  Monitor Closely (1)ketamine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

• ketoconazole
  Contraindicated (1)ketoconazole and sotalol both increase QTc interval. Contraindicated.

• ketoprofen
  Monitor Closely (2)ketoprofen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and ketoprofen both increase serum potassium. Use Caution/Monitor.

• ketorolac
  Monitor Closely (2)ketorolac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and ketorolac both increase serum potassium. Use Caution/Monitor.

• ketorolac intranasal
  Monitor Closely (2)ketorolac intranasal decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and ketorolac intranasal both increase serum potassium. Use Caution/Monitor.

• labetalol
  Monitor Closely (1)labetalol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)labetalol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• lapatinib
  Serious - Use Alternative (1)lapatinib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• lasmiditan
  Monitor Closely (1)sotalol increases effects of lasmiditan by pharmacodynamic synergism. Use Caution/Monitor. Lasmiditan has been associated with a lowering of heart rate (HR). In a drug interaction study, addition of a single 200-mg dose of lasmiditan to propranolol decreased HR by an additional 5 bpm compared to propranolol alone, for a mean maximum of 19 bpm.

• lefamulin
  Serious - Use Alternative (1)lefamulin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• lenvatinib
  Monitor Closely (1)sotalol and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.

• leuprolide
  Contraindicated (1)leuprolide increases toxicity of sotalol by QTc interval. Contraindicated. Increases risk of torsades de pointes.

• levalbuterol
  Monitor Closely (2)sotalol decreases effects of levalbuterol by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• levobetaxolol
  Minor (1)levobetaxolol increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• levodopa
  Monitor Closely (1)levodopa increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.

• levofloxacin
  Serious - Use Alternative (1)levofloxacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• levoketoconazole
  Contraindicated (1)levoketoconazole and sotalol both increase QTc interval. Contraindicated.

• lily of the valley
  Minor (1)sotalol, lily of the valley. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.

• lithium
  Serious - Use Alternative (1)lithium and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• lofepramine
  Contraindicated (1)lofepramine and sotalol both increase QTc interval. Contraindicated.

• lofexidine
  Monitor Closely (1)sotalol and lofexidine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended.Serious - Use Alternative (1)lofexidine, sotalol. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.

• lornoxicam
  Monitor Closely (2)lornoxicam decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and lornoxicam both increase serum potassium. Use Caution/Monitor.

• losartan
  Monitor Closely (2)sotalol, losartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
  losartan and sotalol both increase serum potassium. Use Caution/Monitor.

• lumefantrine
  Contraindicated (1)lumefantrine and sotalol both increase QTc interval. Contraindicated.

• macimorelin
  Serious - Use Alternative (1)macimorelin and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.

• maitake
  Minor (1)maitake increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• maprotiline
  Contraindicated (1)maprotiline and sotalol both increase QTc interval. Contraindicated.

• mavacamten
  Serious - Use Alternative (1)sotalol, mavacamten. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility.

• mavorixafor
  Monitor Closely (1)mavorixafor and sotalol both increase QTc interval. Modify Therapy/Monitor Closely. Mavorixafor causes concentration-dependent QTc prolongation. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required.

• meclofenamate
  Monitor Closely (2)meclofenamate decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and meclofenamate both increase serum potassium. Use Caution/Monitor.

• mefenamic acid
  Monitor Closely (2)mefenamic acid decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and mefenamic acid both increase serum potassium. Use Caution/Monitor.

• mefloquine
  Monitor Closely (1)mefloquine increases levels of sotalol by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia.Serious - Use Alternative (1)mefloquine increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.

• meloxicam
  Monitor Closely (2)meloxicam decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and meloxicam both increase serum potassium. Use Caution/Monitor.

• metaproterenol
  Monitor Closely (2)sotalol decreases effects of metaproterenol by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• methadone
  Serious - Use Alternative (1)methadone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• methyclothiazide
  Monitor Closely (1)sotalol increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

• methylphenidate
  Monitor Closely (1)methylphenidate will decrease the level or effect of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.

• methylphenidate transdermal
  Monitor Closely (1)methylphenidate transdermal decreases effects of sotalol by anti-hypertensive channel blocking. Use Caution/Monitor.

• metipranolol ophthalmic
  Minor (1)metipranolol ophthalmic increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• metolazone
  Monitor Closely (1)sotalol increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• metoprolol
  Monitor Closely (1)metoprolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)metoprolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• mifepristone
  Monitor Closely (1)mifepristone, sotalol. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.

• mirtazapine
  Serious - Use Alternative (1)mirtazapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• moxifloxacin
  Contraindicated (1)moxifloxacin and sotalol both increase QTc interval. Contraindicated.

• moxisylyte
  Monitor Closely (1)moxisylyte and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• nabumetone
  Monitor Closely (2)nabumetone decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and nabumetone both increase serum potassium. Use Caution/Monitor.

• nadolol
  Monitor Closely (1)nadolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)nadolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• naproxen
  Monitor Closely (2)naproxen decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and naproxen both increase serum potassium. Use Caution/Monitor.

• nebivolol
  Monitor Closely (1)nebivolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)nebivolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• neostigmine
  Minor (1)sotalol, neostigmine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia.

• nicardipine
  Monitor Closely (1)sotalol and nicardipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• nifedipine
  Monitor Closely (1)sotalol and nifedipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• nilotinib
  Contraindicated (1)nilotinib and sotalol both increase QTc interval. Contraindicated.

• nisoldipine
  Monitor Closely (1)sotalol and nisoldipine both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• nitroglycerin rectal
  Monitor Closely (1)nitroglycerin rectal, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers blunt the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effects. If beta-blockers are used with nitroglycerin in patients with angina pectoris, additional hypotensive effects may occur.

• noni juice
  Minor (1)sotalol and noni juice both increase serum potassium. Minor/Significance Unknown.

• norepinephrine
  Monitor Closely (2)sotalol decreases effects of norepinephrine by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• nortriptyline
  Contraindicated (1)nortriptyline and sotalol both increase QTc interval. Contraindicated.

• octacosanol
  Minor (1)octacosanol increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• octreotide
  Contraindicated (1)octreotide and sotalol both increase QTc interval. Contraindicated.

• octreotide (Antidote)
  Contraindicated (1)octreotide (Antidote) and sotalol both increase QTc interval. Contraindicated.

• ofloxacin
  Serious - Use Alternative (1)ofloxacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• olanzapine
  Serious - Use Alternative (1)olanzapine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• olanzapine/samidorphan
  Monitor Closely (1)olanzapine/samidorphan increases effects of sotalol by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Monitor blood pressure and reduce antihypertensive drug dosage in accordance with its product labeling.

• olmesartan
  Monitor Closely (2)sotalol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
  olmesartan and sotalol both increase serum potassium. Use Caution/Monitor.

• olodaterol inhaled
  Monitor Closely (2)sotalol, olodaterol inhaled. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor. Beta-blockers and olodaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.
  sotalol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias

• ondansetron
  Serious - Use Alternative (1)ondansetron and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.

• osilodrostat
  Monitor Closely (1)osilodrostat and sotalol both increase QTc interval. Use Caution/Monitor.

• osimertinib
  Monitor Closely (1)osimertinib and sotalol both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

• oxaliplatin
  Monitor Closely (1)oxaliplatin will increase the level or effect of sotalol by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.Serious - Use Alternative (1)oxaliplatin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• oxaprozin
  Monitor Closely (2)oxaprozin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and oxaprozin both increase serum potassium. Use Caution/Monitor.

• oxymetazoline intranasal
  Monitor Closely (1)sotalol increases effects of oxymetazoline intranasal by pharmacodynamic synergism. Use Caution/Monitor. When beta-2 receptors are antagonized by nonselective beta blockers, alpha1 vasoconstriction may be unopposed, thus increasing hypertensive effect. When oxymetazoline is combined with intranasal tetracaine for dental anesthesia, avoid or use an alternant anesthetic in patients taking nonselective beta blockers.

• oxymetazoline topical
  Monitor Closely (1)oxymetazoline topical increases and sotalol decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• ozanimod
  Monitor Closely (1)ozanimod and sotalol both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.

• paliperidone
  Serious - Use Alternative (1)paliperidone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• panobinostat
  Serious - Use Alternative (1)sotalol and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.

• parecoxib
  Monitor Closely (2)parecoxib decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and parecoxib both increase serum potassium. Use Caution/Monitor.

• paroxetine
  Serious - Use Alternative (1)paroxetine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• pasireotide
  Monitor Closely (1)sotalol and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.

• pazopanib
  Monitor Closely (1)pazopanib and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.

• penbutolol
  Monitor Closely (1)penbutolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)penbutolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• pentamidine
  Contraindicated (1)pentamidine and sotalol both increase QTc interval. Contraindicated.

• pentobarbital
  Monitor Closely (1)pentobarbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of pentobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

• perphenazine
  Contraindicated (1)perphenazine and sotalol both increase QTc interval. Contraindicated.

• phenobarbital
  Monitor Closely (1)phenobarbital decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of phenobarbital. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

• phenoxybenzamine
  Monitor Closely (1)phenoxybenzamine and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• phentolamine
  Monitor Closely (1)phentolamine and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

• physostigmine
  Minor (1)sotalol, physostigmine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia.

• pilocarpine
  Minor (1)pilocarpine increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• pimavanserin
  Serious - Use Alternative (1)pimavanserin and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Coadministration may increase the risk of QT prolongation and cardiac arrhythmia.

• pimozide
  Contraindicated (1)pimozide and sotalol both increase QTc interval. Contraindicated.

• pindolol
  Monitor Closely (1)pindolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)pindolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• pirbuterol
  Monitor Closely (2)sotalol decreases effects of pirbuterol by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• piroxicam
  Monitor Closely (2)piroxicam decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and piroxicam both increase serum potassium. Use Caution/Monitor.

• pitolisant
  Serious - Use Alternative (1)sotalol and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.

• ponesimod
  Monitor Closely (2)ponesimod and sotalol both increase pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers may have additive effects on lowering HR. Consider resting HR before initiating ponesimod in patients on stable dose of beta-blocker. Refer to the ponesimod prescribing information for more dosing information.
  ponesimod, sotalol. Either increases effects of the other by QTc interval. Use Caution/Monitor. Consult cardiologist if considering treatment. Class III (eg, amiodarone, dofetilide, sotalol) anti-arrhythmic drugs have been associated with cases of torsades de pointes in patients with bradycardia.

• posaconazole
  Serious - Use Alternative (1)posaconazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• potassium acid phosphate
  Monitor Closely (1)sotalol and potassium acid phosphate both increase serum potassium. Modify Therapy/Monitor Closely.

• potassium chloride
  Monitor Closely (1)sotalol and potassium chloride both increase serum potassium. Modify Therapy/Monitor Closely.

• potassium citrate
  Monitor Closely (1)sotalol and potassium citrate both increase serum potassium. Modify Therapy/Monitor Closely.

• prazosin
  Monitor Closely (1)prazosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of prazosin may be enhanced.

• primaquine
  Serious - Use Alternative (1)primaquine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• primidone
  Monitor Closely (1)primidone decreases levels of sotalol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of primidone. Atenolol, sotalol, nadolol less likely to be affected than other beta blockers.

• procainamide
  Contraindicated (1)procainamide and sotalol both increase QTc interval. Contraindicated.

• prochlorperazine
  Contraindicated (1)prochlorperazine and sotalol both increase QTc interval. Contraindicated.

• promazine
  Contraindicated (1)promazine and sotalol both increase QTc interval. Contraindicated.Monitor Closely (1)promazine, sotalol. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Increased risk of ventricular arrhythmia.

• promethazine
  Contraindicated (1)promethazine and sotalol both increase QTc interval. Contraindicated.

• propofol
  Monitor Closely (1)propofol, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

• propranolol
  Monitor Closely (1)propranolol and sotalol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)propranolol and sotalol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• protriptyline
  Contraindicated (1)protriptyline and sotalol both increase QTc interval. Contraindicated.

• quetiapine
  Monitor Closely (1)quetiapine, sotalol. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.

• quinidine
  Contraindicated (1)quinidine and sotalol both increase QTc interval. Contraindicated.

• quinine
  Monitor Closely (1)sotalol and quinine both increase QTc interval. Use Caution/Monitor.

• quizartinib
  Monitor Closely (1)quizartinib, sotalol. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.

• ranolazine
  Serious - Use Alternative (1)ranolazine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• reishi
  Minor (1)reishi increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• ribociclib
  Serious - Use Alternative (1)ribociclib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• rilpivirine
  Monitor Closely (1)rilpivirine increases toxicity of sotalol by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsade de Pointes.

• risperidone
  Serious - Use Alternative (1)risperidone and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• rivastigmine
  Serious - Use Alternative (1)sotalol increases toxicity of rivastigmine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive bradycardia effect may result in syncope.

• romidepsin
  Monitor Closely (1)romidepsin and sotalol both increase QTc interval. Modify Therapy/Monitor Closely.

• sacubitril/valsartan
  Monitor Closely (2)sotalol, sacubitril/valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
  sacubitril/valsartan and sotalol both increase serum potassium. Use Caution/Monitor.

• salicylates (non-asa)
  Monitor Closely (2)salicylates (non-asa) decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and salicylates (non-asa) both increase serum potassium. Use Caution/Monitor.

• salmeterol
  Monitor Closely (2)sotalol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• salsalate
  Monitor Closely (2)salsalate decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and salsalate both increase serum potassium. Use Caution/Monitor.

• selpercatinib
  Monitor Closely (1)selpercatinib and sotalol both increase QTc interval. Use Caution/Monitor.

• sertraline
  Monitor Closely (1)sertraline and sotalol both increase QTc interval. Use Caution/Monitor.

• sevelamer
  Monitor Closely (1)sevelamer decreases levels of sotalol by increasing elimination. Use Caution/Monitor.

• sevoflurane
  Monitor Closely (1)sevoflurane, sotalol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.Serious - Use Alternative (1)sevoflurane and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• shepherd's purse
  Minor (1)shepherd's purse, sotalol. Other (see comment). Minor/Significance Unknown. Comment: Theoretically, shepherd's purse may interfere with BP control.

• sildenafil
  Monitor Closely (1)sotalol increases effects of sildenafil by additive vasodilation. Use Caution/Monitor. Sildenafil has systemic vasodilatory properties and may further lower blood pressure in patients taking antihypertensive medications. Monitor blood pressure response to sildenafil in patients receiving concurrent blood pressure lowering therapy.

• silodosin
  Monitor Closely (1)silodosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Increased risk of dizziness and orthostatic hypotension when silodosin is administered concurrently with antihypertensives.

• siponimod
  Monitor Closely (1)siponimod, sotalol. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Caution when siponimod is initiated in patients receiving beta-blocker treatment because of additive effects on lowering heart rate. Temporary interruption of beta-blocker may be needed before initiating siponimod. Beta-blocker treatment can be initiated in patients receiving stable doses of siponimod.Serious - Use Alternative (1)siponimod, sotalol. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Because of the potential additive effects on heart rate, siponimod should generally not be initiated in patients taking QT prolonging drugs with known arrhythmogenic properties, heart rate lowering calcium channel blockers, or other drugs that may decrease heart rate. If treatment considered, obtain cardiology consult regarding switching to non-heart-rate lowering drugs or appropriate monitoring for treatment initiation.

• sodium bicarbonate
  Monitor Closely (1)sodium bicarbonate decreases levels of sotalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

• sodium citrate/citric acid
  Monitor Closely (1)sodium citrate/citric acid decreases levels of sotalol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

• sodium sulfate/?magnesium sulfate/potassium chloride
  Monitor Closely (1)sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of sotalol by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .

• sodium sulfate/potassium sulfate/magnesium sulfate
  Monitor Closely (1)sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of sotalol by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .

• solifenacin
  Serious - Use Alternative (1)solifenacin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• sorafenib
  Monitor Closely (1)sorafenib and sotalol both increase QTc interval. Use Caution/Monitor.

• spironolactone
  Monitor Closely (1)sotalol and spironolactone both increase serum potassium. Modify Therapy/Monitor Closely.

• succinylcholine
  Monitor Closely (1)sotalol and succinylcholine both increase serum potassium. Use Caution/Monitor.

• sulfamethoxazole
  Serious - Use Alternative (1)sulfamethoxazole and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• sulfasalazine
  Monitor Closely (2)sulfasalazine decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and sulfasalazine both increase serum potassium. Use Caution/Monitor.

• sulindac
  Monitor Closely (2)sulindac decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and sulindac both increase serum potassium. Use Caution/Monitor.

• sunitinib
  Serious - Use Alternative (1)sunitinib and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• tacrolimus
  Serious - Use Alternative (1)tacrolimus and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• tadalafil
  Monitor Closely (1)tadalafil increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

• telavancin
  Serious - Use Alternative (1)sotalol and telavancin both increase QTc interval. Avoid or Use Alternate Drug.

• telmisartan
  Monitor Closely (2)sotalol, telmisartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
  telmisartan and sotalol both increase serum potassium. Use Caution/Monitor.

• terazosin
  Monitor Closely (1)terazosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Additive hypotensive effects may occur when terazosin is used in combination with sotalol.

• terbutaline
  Monitor Closely (2)sotalol decreases effects of terbutaline by pharmacodynamic antagonism. Use Caution/Monitor.
  sotalol increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• tetrabenazine
  Serious - Use Alternative (1)tetrabenazine and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• theophylline
  Monitor Closely (1)sotalol, theophylline. Other (see comment). Use Caution/Monitor. Comment: Beta blockers (esp. non selective) antagonize theophylline effects, while at the same time increasing theophylline levels and toxicity (mechanism: decreased theophylline metabolism). Smoking increases risk of interaction.

• thioridazine
  Contraindicated (1)thioridazine and sotalol both increase QTc interval. Contraindicated.

• timolol
  Monitor Closely (1)sotalol and timolol both increase serum potassium. Use Caution/Monitor.Serious - Use Alternative (1)sotalol and timolol both increase anti-hypertensive channel blocking. Avoid or Use Alternate Drug.

• tizanidine
  Minor (1)tizanidine increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.

• tolfenamic acid
  Monitor Closely (2)tolfenamic acid decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and tolfenamic acid both increase serum potassium. Use Caution/Monitor.

• tolmetin
  Monitor Closely (2)tolmetin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.
  sotalol and tolmetin both increase serum potassium. Use Caution/Monitor.

• tolvaptan
  Monitor Closely (1)sotalol and tolvaptan both increase serum potassium. Use Caution/Monitor.

• toremifene
  Serious - Use Alternative (1)sotalol and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.

• torsemide
  Monitor Closely (1)sotalol increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.

• trazodone
  Contraindicated (1)trazodone and sotalol both increase QTc interval. Contraindicated.

• treprostinil
  Minor (1)treprostinil increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.

• triamterene
  Monitor Closely (1)sotalol and triamterene both increase serum potassium. Modify Therapy/Monitor Closely.

• triclabendazole
  Monitor Closely (1)triclabendazole and sotalol both increase QTc interval. Use Caution/Monitor.

• trifluoperazine
  Contraindicated (1)trifluoperazine and sotalol both increase QTc interval. Contraindicated.

• trimethoprim
  Serious - Use Alternative (1)sotalol and trimethoprim both increase QTc interval. Avoid or Use Alternate Drug.

• trimipramine
  Contraindicated (1)trimipramine and sotalol both increase QTc interval. Contraindicated.

• triptorelin
  Serious - Use Alternative (1)triptorelin increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

• tropisetron
  Serious - Use Alternative (1)sotalol and tropisetron both increase QTc interval. Avoid or Use Alternate Drug.

• umeclidinium bromide/vilanterol inhaled
  Serious - Use Alternative (2)sotalol, umeclidinium bromide/vilanterol inhaled. pharmacodynamic antagonism. Avoid or Use Alternate Drug. If a beta-blocker must be used in patients with COPD taking a beta-agonist, consider using a beta-blocker that is beta-1 selective .
  sotalol increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

• valsartan
  Monitor Closely (2)sotalol, valsartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy.
  valsartan and sotalol both increase serum potassium. Use Caution/Monitor.

• vandetanib
  Serious - Use Alternative (1)sotalol, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.

• vemurafenib
  Serious - Use Alternative (1)vemurafenib and sotalol both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.

• venlafaxine
  Serious - Use Alternative (1)sotalol and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug.

• verapamil
  Monitor Closely (1)sotalol and verapamil both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)verapamil, sotalol. Either increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia.

• vilanterol/fluticasone furoate inhaled
  Serious - Use Alternative (2)sotalol, vilanterol/fluticasone furoate inhaled. pharmacodynamic antagonism. Avoid or Use Alternate Drug. If a beta-blocker must be used in patients with COPD taking a beta-agonist, consider using a beta-blocker that is beta-1 selective .
  sotalol increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

• voclosporin
  Monitor Closely (1)voclosporin, sotalol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

• voriconazole
  Serious - Use Alternative (1)sotalol and voriconazole both increase QTc interval. Avoid or Use Alternate Drug.

• vorinostat
  Serious - Use Alternative (1)vorinostat and sotalol both increase QTc interval. Avoid or Use Alternate Drug.

• xipamide
  Monitor Closely (1)xipamide increases effects of sotalol by pharmacodynamic synergism. Use Caution/Monitor.

• yohimbe
  Minor (1)sotalol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

• ziprasidone
  Contraindicated (1)sotalol and ziprasidone both increase QTc interval. Contraindicated.